Wednesday, April 29, 2020 2:39:33 AM
They have no product revenue.
I expect shares to be diluted after earnings.
Read their 10k. I guess it's a gamble play incase one day they do get approval.
Recent SNDX News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 10:00:08 PM
- Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial • PR Newswire (US) • 12/09/2024 12:30:00 PM
- Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting • PR Newswire (US) • 12/07/2024 11:15:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 12/06/2024 09:28:33 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 12/03/2024 09:05:00 PM
- Syndax Announces Participation at the Citi 2024 Global Healthcare Conference • PR Newswire (US) • 11/27/2024 12:00:00 PM
- Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation • PR Newswire (US) • 11/15/2024 10:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 12:05:36 PM
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib • PR Newswire (US) • 11/12/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2024 09:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 09:02:08 PM
- Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 11/05/2024 09:01:00 PM
- Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 • PR Newswire (US) • 11/05/2024 02:01:00 PM
- Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting • PR Newswire (US) • 11/05/2024 02:00:00 PM
- Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting • PR Newswire (US) • 11/05/2024 02:00:00 PM
- Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ • PR Newswire (US) • 11/04/2024 09:01:00 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 11/01/2024 08:05:00 PM
- Syndax Announces Participation in November Investor Conferences • PR Newswire (US) • 11/01/2024 11:00:00 AM
- Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 • PR Newswire (US) • 10/29/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/04/2024 08:05:00 PM
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease • PR Newswire (US) • 09/18/2024 09:15:00 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 09/06/2024 08:05:00 PM
- Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD) • Business Wire • 08/15/2024 08:15:00 PM
- Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD) • Business Wire • 08/15/2024 10:26:00 AM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM